Y
Yinan Zhang
Researcher at University of Texas Southwestern Medical Center
Publications - 7
Citations - 180
Yinan Zhang is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: Natalizumab & Fingolimod. The author has an hindex of 5, co-authored 5 publications receiving 111 citations.
Papers
More filters
Journal ArticleDOI
Immunological Aspects of Approved MS Therapeutics.
Paulus S. Rommer,Ron Milo,May H. Han,Sammita Satyanarayan,Johann Sellner,Larissa Hauer,Zsolt Illes,Clemens Warnke,Sarah Laurent,Martin S. Weber,Yinan Zhang,Olaf Stüve +11 more
TL;DR: The objective of this review is to present the modes of action of these drugs and their effects on the immunopathogenesis of MS and each agent's clinical development and potential side effects are discussed.
Journal ArticleDOI
Evolution of clinical trials in multiple sclerosis.
TL;DR: The replacement of the placebo arm by an active comparator arm in trials have raised the cost of trials by requiring larger sample sizes to detect on-study changes in treatment effects, and efforts to improve trial efficiency in RRMS have focused on exploring adaptive designs and relying on sensitive magnetic resonance imaging measures of disease activity.
Journal ArticleDOI
Use of interleukin-2 for management of natalizumab-associated progressive multifocal leukoencephalopathy: case report and review of literature:
TL;DR: A 51-year-old woman with relapsing–remitting multiple sclerosis and 3-year history of natalizumab use developed expressive aphasia and became more responsive and regained right lower extremity antigravity strength.
Journal ArticleDOI
Clinical trials in multiple sclerosis: potential future trial designs.
Navid Manouchehri,Yinan Zhang,Amber Salter,Rehana Z. Hussain,Hans-Peter Hartung,Bernhard Hemmer,Ralf A. Linker,Benjamin M. Segal,Gary Cutter,Olaf Stüve +9 more
TL;DR: This approach may increase the efficiency of MS trials through homogenization of patient population and minimization of nonresponders in study groups, providing the potential for the development of targeted therapies.
Journal ArticleDOI
Differential antibody response to COVID-19 vaccines across immunomodulatory therapies for multiple sclerosis
Sammita Satyanarayan,Neha Safi,Tali Sorets,Susan Filomena,Yinan Zhang,Sylvia Klineova,Michelle Fabian,Sam Horng,Stephanie Tankou,Aaron Miller,Stephen Krieger,Fred D. Lublin,James F. Sumowski,Ilana Katz Sand +13 more
TL;DR: In this paper , the impact of DMTs on antibody response to COVID-19 vaccination among MS patients was investigated, and multivariable logistic regression analyses were used to identify clinical and demographic predictors of antibody response.